Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGe LiuQWQian WangQYQingsong Yin

Discussion

Loading...

Member takes

Overview

Real-world study reveals blinatumomab shows efficacy in treating minimal residual disease in B-ALL patients, suggesting potential for shorter regimens.

Key Points

  • This study examines the efficacy of a 14-day blinatumomab regimen for newly diagnosed B-ALL patients.
  • Retrospective real-world study of B-ALL patients treated with blinatumomab from Jan 2022 to May 2025
  • Inclusion of Ph-positive and Ph-negative patients receiving induction and consolidation treatments
  • Analysis of treatment outcomes, including overall survival and event-free survival rates.
  • Ph+ patients achieved a complete remission rate of 100% with the 14-day regimen
  • Ph- patients had a remission rate of 86.5% and 87.5% achieved minimal residual disease negativity
  • Early expansion of CD8+ effector T cells could predict treatment response.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d273https://doi.org/10.1182/blood-2025-3336
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025
  3. 3Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  4. 4Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  5. 5“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”2025